TEC-话题@MedSci

#TEC#

484篇内容 | 2670人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652360, encodeId=90b4165236062, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=J Biomed Nanotechnol：前列腺素E2在仿生三维纳米纤维支架上调节骨形态发生蛋白-2诱导的成骨分化, objectType=article, longId=176581, objectId=ba951e65818f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba951e65818f, replyNumber=0, likeNumber=67, createdTime=2020-03-29, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba951e65818f, moduleTitle=J Biomed Nanotechnol：前列腺素E2在仿生三维纳米纤维支架上调节骨形态发生蛋白-2诱导的成骨分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba951e65818f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652351, encodeId=b8861652351de, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Artif Cells Nanomed Biotechnol：FAK在滑膜间充质干细胞中通过Wnt和MAPK信号通路介导BMP9诱导的成骨分化, objectType=article, longId=174583, objectId=e2b61e4583cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2b61e4583cc, replyNumber=0, likeNumber=63, createdTime=2019-09-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2b61e4583cc, moduleTitle=Artif Cells Nanomed Biotechnol：FAK在滑膜间充质干细胞中通过Wnt和MAPK信号通路介导BMP9诱导的成骨分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2b61e4583cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652393, encodeId=ac5e16523934d, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, objectType=article, longId=185333, objectId=36af18533328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af18533328, replyNumber=0, likeNumber=69, createdTime=2020-06-01, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af18533328, moduleTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af18533328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652408, encodeId=82861652408e3, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=J Nanobiotechnology：氧化铈纳米颗粒改善对乙酰氨基酚引起的肝损伤和部分肝切除术后肝脏的再生, objectType=article, longId=190337, objectId=dea019033ee5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dea019033ee5, replyNumber=0, likeNumber=65, createdTime=2020-10-27, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea019033ee5, moduleTitle=J Nanobiotechnology：氧化铈纳米颗粒改善对乙酰氨基酚引起的肝损伤和部分肝切除术后肝脏的再生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dea019033ee5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652344, encodeId=e478165234459, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Beilstein J Nanotechnol：PEG-nGO诱导的体内氧化应激的全身作用, objectType=article, longId=168017, objectId=08a016801e31, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08a016801e31, replyNumber=0, likeNumber=61, createdTime=2019-10-11, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08a016801e31, moduleTitle=Beilstein J Nanotechnol：PEG-nGO诱导的体内氧化应激的全身作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08a016801e31)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652370, encodeId=4f9516523e03d, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Diabetes Technol Ther：人工智能VS.眼科医生 | 糖尿病视网膜病变筛查谁更强, objectType=article, longId=179466, objectId=ba321e946628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba321e946628, replyNumber=0, likeNumber=69, createdTime=2020-03-19, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba321e946628, moduleTitle=Diabetes Technol Ther：人工智能VS.眼科医生 | 糖尿病视网膜病变筛查谁更强, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba321e946628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652415, encodeId=308416524159a, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=两款新冠病毒疫苗获批临床试验BioNTech/辉瑞mRNA疫苗和津大学腺病毒疫苗, objectType=article, longId=192847, objectId=447019284ed3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=447019284ed3, replyNumber=0, likeNumber=91, createdTime=2021-01-25, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=447019284ed3, moduleTitle=两款新冠病毒疫苗获批临床试验BioNTech/辉瑞mRNA疫苗和津大学腺病毒疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=447019284ed3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652405, encodeId=5daa1652405d6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=PureTech通过减少纤维化和炎症来治疗淋巴水肿的候选药LYT-100，其临床试验首位参与者开始接受治疗, objectType=article, longId=189496, objectId=66d91894967c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66d91894967c, replyNumber=0, likeNumber=84, createdTime=2020-08-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66d91894967c, moduleTitle=PureTech通过减少纤维化和炎症来治疗淋巴水肿的候选药LYT-100，其临床试验首位参与者开始接受治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66d91894967c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652367, encodeId=642d165236e84, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nature Biotechnology：利用血液代谢组预测肠道微生物组的多样性, objectType=article, longId=178717, objectId=a1601e871742, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1601e871742, replyNumber=0, likeNumber=69, createdTime=2020-07-31, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1601e871742, moduleTitle=Nature Biotechnology：利用血液代谢组预测肠道微生物组的多样性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1601e871742)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652399, encodeId=247f165239950, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotech：人工合成酶可能为线粒体功能异常疾病提供新疗法, objectType=article, longId=186514, objectId=7efe1865146c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7efe1865146c, replyNumber=0, likeNumber=113, createdTime=2020-07-09, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7efe1865146c, moduleTitle=Nat Biotech：人工合成酶可能为线粒体功能异常疾病提供新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7efe1865146c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652357, encodeId=d3bb165235e26, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应, objectType=article, longId=176417, objectId=1f141e6417a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f141e6417a6, replyNumber=0, likeNumber=58, createdTime=2020-04-08, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f141e6417a6, moduleTitle=Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f141e6417a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652381, encodeId=8030165238138, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Nat Biotechnol:科学家首次实现活细胞RNA标记与无背景成像, objectType=article, longId=182572, objectId=4ffd1825e244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ffd1825e244, replyNumber=0, likeNumber=0, createdTime=2020-02-05, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ffd1825e244, moduleTitle=Nat Biotechnol:科学家首次实现活细胞RNA标记与无背景成像, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ffd1825e244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652353, encodeId=a27316523535f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=BioNTech为其mRNA癌症个性化疫苗平台融资2.9亿欧元, objectType=article, longId=175402, objectId=7fe01e5402fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fe01e5402fe, replyNumber=0, likeNumber=86, createdTime=2020-05-24, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fe01e5402fe, moduleTitle=BioNTech为其mRNA癌症个性化疫苗平台融资2.9亿欧元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fe01e5402fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652350, encodeId=bd95165235087, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Artif Cells Nanomed Biotechnol：组胺H1型受体（H1R）在调节成骨细胞分化和矿化中的作用, objectType=article, longId=174511, objectId=f3171e451142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3171e451142, replyNumber=0, likeNumber=68, createdTime=2020-03-30, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3171e451142, moduleTitle=Artif Cells Nanomed Biotechnol：组胺H1型受体（H1R）在调节成骨细胞分化和矿化中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3171e451142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652388, encodeId=4a5b165238894, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=ASIT Biotech花粉过敏药物的功效, objectType=article, longId=184295, objectId=a0ae1842958e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0ae1842958e, replyNumber=0, likeNumber=81, createdTime=2020-07-16, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0ae1842958e, moduleTitle=ASIT Biotech花粉过敏药物的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0ae1842958e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652371, encodeId=194a16523e17e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, objectType=article, longId=180179, objectId=775a1801e9d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=775a1801e9d4, replyNumber=0, likeNumber=97, createdTime=2020-05-21, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=775a1801e9d4, moduleTitle=2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=775a1801e9d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652328, encodeId=3ea7165232820, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=FDA接受Genentech的XOFLUZA的补充新药申请，用于治疗高危并发症患者的流感, objectType=article, longId=161817, objectId=0ded16181eb0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ded16181eb0, replyNumber=0, likeNumber=46, createdTime=2020-02-12, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ded16181eb0, moduleTitle=FDA接受Genentech的XOFLUZA的补充新药申请，用于治疗高危并发症患者的流感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ded16181eb0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652395, encodeId=350e1652395ee, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, objectType=article, longId=185527, objectId=8ca718552e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ca718552e25, replyNumber=0, likeNumber=83, createdTime=2020-10-24, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ca718552e25, moduleTitle=因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ca718552e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652338, encodeId=4ad51652338ac, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性, objectType=article, longId=165380, objectId=4e2c165380ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c165380ae, replyNumber=0, likeNumber=50, createdTime=2019-06-20, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c165380ae, moduleTitle=Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2c165380ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652359, encodeId=1b85165235953, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, objectTitle=研发日报丨一线治疗NSCLC！罗氏Tecentriq组合方案获CHMP推荐, objectType=article, longId=176562, objectId=1a791e656255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a791e656255, replyNumber=0, likeNumber=56, createdTime=2020-07-13, rootId=0, userName=shock_melon, userId=852f24292001, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a791e656255, moduleTitle=研发日报丨一线治疗NSCLC！罗氏Tecentriq组合方案获CHMP推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a791e656255)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TEC

2020-05-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

J Biomed Nanotechnol：前列腺素E2在仿生三维纳米纤维支架上调节骨形态发生蛋白-2诱导的成骨分化

2020-03-29

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Artif Cells Nanomed Biotechnol：FAK在滑膜间充质干细胞中通过Wnt和MAPK信号通路介导BMP9诱导的成骨分化

2019-09-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA

2020-06-01

shock_melon (审核中...)

前往app查看评论内容

#TEC#

J Nanobiotechnology：氧化铈纳米颗粒改善对乙酰氨基酚引起的肝损伤和部分肝切除术后肝脏的再生

2020-10-27

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Beilstein J Nanotechnol：PEG-nGO诱导的体内氧化应激的全身作用

2019-10-11

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Diabetes Technol Ther：人工智能VS.眼科医生 | 糖尿病视网膜病变筛查谁更强

2020-03-19

shock_melon (审核中...)

前往app查看评论内容

#TEC#

两款新冠病毒疫苗获批临床试验BioNTech/辉瑞mRNA疫苗和津大学腺病毒疫苗

2021-01-25

shock_melon (审核中...)

前往app查看评论内容

#TEC#

PureTech通过减少纤维化和炎症来治疗淋巴水肿的候选药LYT-100，其临床试验首位参与者开始接受治疗

2020-08-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nature Biotechnology：利用血液代谢组预测肠道微生物组的多样性

2020-07-31

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotech：人工合成酶可能为线粒体功能异常疾病提供新疗法

2020-07-09

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应

2020-04-08

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Nat Biotechnol:科学家首次实现活细胞RNA标记与无背景成像

2020-02-05

shock_melon (审核中...)

前往app查看评论内容

#TEC#

BioNTech为其mRNA癌症个性化疫苗平台融资2.9亿欧元

2020-05-24

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Artif Cells Nanomed Biotechnol：组胺H1型受体（H1R）在调节成骨细胞分化和矿化中的作用

2020-03-30

shock_melon (审核中...)

前往app查看评论内容

#TEC#

ASIT Biotech花粉过敏药物的功效

2020-07-16

shock_melon (审核中...)

前往app查看评论内容

#TEC#

2019 ESMO：罗氏的PD-L1单抗Tecentriq与VEGF单抗Avastin联合针对无法切除的肝细胞癌患者的Ib期研究中显示出令人鼓舞的结果

2020-05-21

shock_melon (审核中...)

前往app查看评论内容

#TEC#

FDA接受Genentech的XOFLUZA的补充新药申请，用于治疗高危并发症患者的流感

2020-02-12

shock_melon (审核中...)

前往app查看评论内容

#TEC#

因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

2020-10-24

shock_melon (审核中...)

前往app查看评论内容

#TEC#

Lancet oncol：曲妥珠单抗deruxtecan用于HER2阳性的胃或胃食管交界癌的疗效和安全性

2019-06-20

shock_melon (审核中...)

前往app查看评论内容

#TEC#

研发日报丨一线治疗NSCLC！罗氏Tecentriq组合方案获CHMP推荐

2020-07-13

科室
- - 订阅+
  - 更多科室
工具
服务